Gilead Sciences completes tender offer for all outstanding shares of Pharmasset, Inc.
12 January 2012 | By Gilead Sciences
Following the merger, Pharmasset will become a wholly-owned subsidiary of Gilead...
List view / Grid view
12 January 2012 | By Gilead Sciences
Following the merger, Pharmasset will become a wholly-owned subsidiary of Gilead...
6 January 2012 | By Gilead Sciences
Gilead Sciences, Inc. has received early termination of the required waiting period...
28 November 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Eviplera®...
21 November 2011 | By Gilead Sciences
Gilead Sciences, Inc., will acquire Pharmasset, Inc., for $137 per share in cash...
15 November 2011 | By Gilead Sciences
Gilead Sciences, Inc. has entered into a license agreement with Tibotec Pharmaceuticals...
5 November 2011 | By
New long-term data show no development of resistance...
26 October 2011 | By Bristol-Myers Squibb Company
Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination...
24 October 2011 | By Gilead Sciences Inc
Gilead & GlobeImmune enter into an exclusive worldwide license & collaboration agreement...
5 October 2011 | By Gilead Sciences
Gilead Sciences, Inc. and Boehringer Ingelheim have entered into a licensing agreement...
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
5 September 2011 | By Gilead Sciences, Inc.
Change does not affect ongoing "All Oral" clinical trials evaluating multiple direct-acting antivirals in combination...
15 August 2011 | By Gilead Sciences
Phase 3 clinical trial met its primary objective...
10 August 2011 | By Gilead Sciences Inc
A new complete once-daily, single-tablet regimen for HIV-1 infection in treatment-naïve adults...
8 August 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. has signed a definitive agreement...
12 July 2011 | By Gilead Sciences
Gilead Sciences, Inc. announced an expansion of its global access program...